|
Prognostic factors
|
Cases (%)
|
Univariate Pa
|
Multivariate
|
|---|
|
HR (95% CI)
|
Pb
|
|---|
|
Age (years)
| |
0.281
| |
0.495
|
|
≤ 57 (median)
|
57(50.4)
| |
1.000
| |
|
> 57 (median)
|
56(49.6)
| |
1.010(0.982–1.037)
| |
|
FIGO Stage
| |
0.002
| |
0.047
|
|
Early(I + II)
|
17(15.0)
| |
1.000
| |
|
Late(III + IV)
|
96(85.0)
| |
3.241(1.065–10.879)
| |
|
Residual tumor (cm)
| |
0.042
| |
0.543
|
|
≤ 1
|
104(92.0)
| |
1.000
| |
|
> 1
|
9(8.0)
| |
1.300 (0.558–3.027)
| |
|
Ascites
| |
0.085
| |
0.690
|
|
No
|
11(9.7)
| |
1.000
| |
|
Yes
|
102(90.3)
| |
1.280(0.380–4.311)
| |
|
Endometriosis
| |
0.140
| |
0.568
|
|
No
|
101(89.4)
| |
1.000
| |
|
Yes
|
12(10.6)
| |
1.245(0.586–2.647)
| |
|
Chemotherapeutic response
| |
0.000
| |
0.000
|
|
Platinum sensitive
|
77(72.0)
| |
1.000
| |
|
Platinum resistant
|
30(28.0)
| |
3.573(2.056–6.210)
| |
- Log rank test
-
awithout adjustment
- Cox proportional hazards regression analysis
-
bwith adjustment for age, FIGO stage, residual tumor, ascites, endometriosis, and chemotherapeutic response
- Bold value denotes P with statistical significance
